|Other Names||Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform, PP2A subunit B isoform B55-beta, PP2A subunit B isoform PR55-beta, PP2A subunit B isoform R2-beta, PP2A subunit B isoform beta, PPP2R2B|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8600c was selected from the Center region of human PPP2R2B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might direct the localization of the catalytic enzyme to a particular subcellular compartment. Within the PP2A holoenzyme complex, isoform 2 is required to promote proapoptotic activity (By similarity). Isoform 2 regulates neuronal survival through the mitochondrial fission and fusion balance (By similarity).|
|Cellular Location||Isoform 1: Cytoplasm. Cytoplasm, cytoskeleton. Membrane|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PPP2R2B belongs to the phosphatase 2 regulatory subunit B family. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The B regulatory subunit might modulate substrate selectivity and catalytic activity. This protein is a beta isoform of the regulatory subunit B55 subfamily.
Rajkiewicz,M., et.al., Neurol. Neurochir. Pol. 42 (6), 497-504 (2008)Ben-Israel,H., et.al., J. Virol. 82 (19), 9381-9388 (2008)Strack,S., et.al., J. Comp. Neurol. 392 (4), 515-527 (1998)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.